Skip to main content

Table 5 Incremental cost-effectiveness ratios in 2002 prices for the preferred (not dominated) strategies from Bolin et al. [10], assuming a five-year dwell time

From: Re-interpreting the data on the cost and effectiveness of population screening for colorectal cancer in Australia

Strategy

Cost ($)

Incremental changes in cost ($)

Effectiveness (LYG)

Incremental changes in effectiveness (LYG)

Average cost-effectiveness ratio ($)

Incremental cost-effectiveness ratio ($)

 

(a)

(b)

(c)

(d)

(a)/(c)

(b)/(d)

EXISTING PRACTICE

0

 

0

 

(Undefined)

 

DCBE3

307,911,416

307,911,416

6,184

6,184

49,792

49,792

FOBT1+DBCE3

424,911,339

116,999,923

7,020

836

60,529

139,952

  1. Note: Other options rejected on the grounds of 'simple' and 'extended' dominance, see text for a discussion.